UltraSight raises $24 million to expand in the US — Jerusalem Post
In Israel, UltraSight, which the Jerusalem Post describes as a company with Israeli leadership, announced that it had raised $24 million in a Series B2 funding round. The funds are planned to be directed toward expansion in the US market, as well as the development of new solutions for intensive care units and circulatory support systems.
Round participants
The funding round was led by Alive HealthTech Growth Fund. Deep Insight, Star51 Capital, Connecticut Innovations, and eHealth Ventures also participated. Among existing investors that joined the financing, the company named Mayo Clinic Ventures, New York University, and Iron Nation.
UltraSight CEO and co-founder Davidi Wortman said that the company’s portfolio of solutions cleared by the US Food and Drug Administration is expanding to support a broader range of cardiac imaging tasks. According to him, the funding is intended to facilitate wider adoption of the technology and the development of strategic partnerships.
Mayo Clinic said that the clinic has a financial interest in UltraSight’s technology. Any income from this interest is planned to be used to support nonprofit activities in patient care, education, and research.
More current news is available on the UA.News Telegram channel Telegram.
Platform for cardiac imaging
UltraSight develops artificial intelligence-powered cardiac ultrasound technology. According to the company, its Echosystem platform is already used at more than ten commercial intensive care sites.
Alive co-founder and managing partner Dudi Klein said that UltraSight combines clinical data with a commercial model that can be scaled amid limited access to services and staff shortages. Interventional cardiologist and Alive general partner Professor Rafi Beyar believes that the company’s system can transform the use of imaging for diagnosing and treating structural heart disease.
Recently appointed UltraSight board chair Rick Jeffrion said that the funding is expected to help the company scale its artificial intelligence platform for cardiac care.
